These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 30025814)

  • 21. Ψ-Xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance.
    Craig SL; Gault VA; Hamscher G; Irwin N
    J Endocrinol; 2020 May; 245(2):219-230. PubMed ID: 32130206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
    Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
    Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
    O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
    Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.
    Lamont BJ; Drucker DJ
    Diabetes; 2008 Jan; 57(1):190-8. PubMed ID: 17928394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
    Bhat VK; Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
    Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
    Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.
    Wice BM; Wang S; Crimmins DL; Diggs-Andrews KA; Althage MC; Ford EL; Tran H; Ohlendorf M; Griest TA; Wang Q; Fisher SJ; Ladenson JH; Polonsky KS
    J Biol Chem; 2010 Jun; 285(26):19842-53. PubMed ID: 20421298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25.
    Martin CM; Gault VA; McClean S; Flatt PR; Irwin N
    Biochem Pharmacol; 2012 Aug; 84(3):312-9. PubMed ID: 22561048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety.
    Taylor AI; Irwin N; McKillop AM; Patterson S; Flatt PR; Gault VA
    J Endocrinol; 2010 Oct; 207(1):87-93. PubMed ID: 20631047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging therapeutic potential for xenin and related peptides in obesity and diabetes.
    Craig SL; Gault VA; Irwin N
    Diabetes Metab Res Rev; 2018 Sep; 34(6):e3006. PubMed ID: 29633491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
    Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
    Parker JC; Irwin N; Lavery KS; Green BD; O'Harte FP; Gault VA; Flatt PR
    Biol Chem; 2007 Feb; 388(2):221-6. PubMed ID: 17261085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
    McClean PL; Irwin N; Cassidy RS; Holst JJ; Gault VA; Flatt PR
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1746-55. PubMed ID: 17848629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.
    Wice BM; Reeds DN; Tran HD; Crimmins DL; Patterson BW; Dunai J; Wallendorf MJ; Ladenson JH; Villareal DT; Polonsky KS
    Diabetes; 2012 Jul; 61(7):1793-800. PubMed ID: 22522617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
    Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
    Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice.
    Baggio L; Kieffer TJ; Drucker DJ
    Endocrinology; 2000 Oct; 141(10):3703-9. PubMed ID: 11014225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.